What the October peptide compounding policy actually changed, and what it didn’t
For qualified researchers. Clarion Peptides products are sold for laboratory research use only. They are not for people or animals. Updated November 10, 2026.
At the end of October, HHS issued a policy using FDA enforcement discretion to let 503A compounding pharmacies prepare six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The Federal Register published it on October 30, 2026.1 It followed July votes of FDA’s Pharmacy Compounding Advisory Committee. BPC-157, for example, passed 8 to 6 with one abstention.3
Most of the coverage since has picked a lane. One version reads it as vindication. The other reads it as regulatory collapse. Both make the same error: they treat the policy as a verdict on whether these compounds do anything. It isn’t one. It’s a statement about who the agency intends to pursue.
Enforcement discretion is not approval
The policy does not approve these six peptides, and it does not conclude they are safe or effective. It says the government does not currently intend to act against compounders who meet its conditions while the formal rule is pending.2 That is a posture, and postures are revisable. Anyone building a business on the assumption that this is settled law has misread the document.
It runs through a prescription
Section 503A covers patient-specific prescriptions, and the policy keeps that requirement in full.2 It is a clinical channel with a prescriber in it. The policy did not create a consumer channel.
It does not reach research-use-only supply
This is the part we’d rather not write, because it is the part that doesn’t flatter us. We sell research-use-only material, and we list all six of the named compounds. The policy covers compounders, and it says plainly that it does not extend to research-use-only ingredients.2 It does not cover us, it does not legitimize what we do, and it changes nothing about the terms we sell under.
HHS went further. It said one aim of the policy is to discourage the widespread use of peptides labeled “research use only” from foreign manufacturers, which it described as a safety risk to US patients.2 Any supplier telling you this policy made their catalog legal is describing a document they have not read.
FDA’s own scientists objected
FDA’s drug reviewers recommended against adding these peptides, citing too little information on safety and effectiveness.2,3 The committee voted in favor anyway, by narrow margins, and HHS went ahead on that vote. That disagreement is in the record, and it is a reasonable thing to weigh.
The policy puts the weight on the certificate
To qualify, a pharmacy has to use peptide ingredient from an FDA-registered original manufacturer that follows drug manufacturing rules (CGMP). The ingredient needs a valid certificate of analysis with test results for identity, purity, potency and harmful contaminants, and the manufacturer’s facility location must appear on it.2
That is a higher bar than research-use-only supply is held to, and we don’t meet all of it today. Our lab reports cover identity and purity, and in most cases net content. None covers contaminants such as endotoxin, and seven of our lots rely on reports our supplier ordered. Here is where we stand.
So the useful question this policy raises is not only is it allowed. It is does a lab report that a buyer can check stand behind this exact lot, and what does it cover. That is the question worth asking any supplier, including us.
Sources
- Federal Register, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, document 2026-22192, published October 30, 2026.
- Holland & Knight, HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides, November 4, 2026 (summary of the policy’s conditions and stated aims).
- ABC News, FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list, July 2026.
All products sold by Clarion Peptides are for laboratory research use only. Not for human or veterinary use. Nothing on this page is a claim about the effects of any compound.
